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The mysteries of H. pylori in health and disease
The discovery of H. pylori by Warren and Marshall (Lancet, 1984) was greeted with skepticism initially 
but ultimately earned them the 2005 Nobel Prize in Physiology or Medicine. Today, we know that this 
bacterium colonizes the gastric mucosa in 50% of the world’s population. Its fundamental role in diseases 
such as chronic gastritis, duodenal and gastric ulcers, and gastric cancer has been extensively studied. 
Only a tiny fraction of people infected with H. pylori, however, will develop gastric cancer. Furthermore, 
in some diseases (Barrett’s esophagus) it may somehow be protective. The link between infection and 
actual clinical outcome may be genetically determined across a spectrum of virulence. Does H. pylori 
somehow factor in hepatobiliary disease? Apparently so, according to Boonyanugomol et al. from Bangkok. 
For the fi rst time, these authors investigated well known H. pylori virulence-associated genes in hepato-
biliary patients and correlated their prevalence with actual clinical outcomes. DNA was extracted from 
58 cholangiocarcinoma and 22 cholelithiasis patients known to be H. pylori-positive. A virulence geno-
type so to speak for each patient was developed by PCR amplifi cation, DNA sequencing and phylogenetic 
analysis. To tighten the association to hepatobiliary disease, patients with gastroduodenal diseases were 
deliberately excluded. H. pylori overall and its cagA/cagE virulence genes were detected signifi cantly more 
often in cholangiocarcinoma (30%) than in cholelithiasis (4%) patients. It’s no surprise that the authors 
raise the question of cause and effect for biliary cancer. But more simply, why is H. pylori even found in 
the biliary system? How does it get there and why? Is it dangerous for the host or perhaps even mutually-
benefi cial? How does environment contribute to the phylogenetic variations of its virulence? This report 
will indeed stimulate new questions about H. pylori in hepatobiliary disease. Whatever the answers, the 
mysteries of H. pylori in both health and disease will deepen.
Mark Callery
Duodenal GISTs don’t always require pancreaticoduodenectomy
Gastrointestinal stromal tumours are rare mesenchymal tumours that can arise anywhere in the GI tract. 
Although duodenal involvement is rare, the surgical decision making can be complex due to the local 
anatomical relationships that need to be considered. In this issue of HPB, Kamath and colleagues from 
the Mayo Clinic describe a series of 41 patients who were identifi ed over a 13 year period. For these 
patients the most common presentations were due to complications of acute or chronic GI haemorrhage, 
although it is important to recognize that incidental diagnosis at endoscopy was also a frequent source 
of presentation. Although the tumours were distributed through out the duodenum in 26 of the 41 
patients, the tumour was located within the second part of the duodenum. The key message that this 
paper provides is that for these 26 patients only 11 required pancreaticoduodenectomy to achieve a clear 
surgical margin. As the authors point out, for GIST’s radical onocological resections aimed at performing 
a nodal clearance are not required as these tumours rarely spread to lymph nodes. Therefore the underly-
ing surgical aims should be to achieve a negative margin while preserving underlying function and 
minimizing morbidity. Given that local resection can be performed with less morbidity than pancreati-
coduodenctomy this should be considered as the fi rst option.
Saxon Connor
Consider the venous outfl ow as well as the liver infl ow during staged 
hepatic resections
The success of chemotherapy for colorectal hepatic metastases and the improvements in technique and 
anaesthesia, which have lead to improved safety in liver surgery, have meant that more patients can have 
the opportunity to undergo liver resection. Staged liver resection is defi ned as a planned procedure where 
part of the liver is removed and regeneration of the liver remnant is allowed to occur before a second 
surgery to remove residual tumour is performed. This type of surgery can be diffi cult for a number of 
reasons not least it demands that regeneration of the liver remnant will occur to allow the second pro-
cedure to take place safely. Chemotherapy induced sinusoidal obstruction syndrome, steatosis and fi brosis 
can all limit this regeneration. In surgical terms most of the attention in staged resection has concerned 
the hepatic infl ow as a regulator of liver regeneration. In this issue of HPB, Faitot et al. explore the infl u-
ence of venous congestion and venous drainage as a determinant of regenerative capacity. They studied 
patients who underwent a right hepatectomy in whom the middle hepatic vein tributaries to segment IV 
were removed or not. They demonstrated that preservation of the tributaries of segment IV draining into 
the middle hepatic vein permitted greater regeneration of segment IV after right hepatectomy than in 
patients where these tributaries were sacrifi ced. Planning staged resections is never easy, but this study 
highlights the importance of giving serious consideration to the venous drainage of the future liver 
remnant to ensure maximum regeneration and thereby improve ease and safety of subsequent liver 
resection.
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